Description: |
This is a multicenter, open-label, Phase 2 study. Subjects will be randomized to either the investigational product, DN24-02, or to standard of care. The purpose of this study is to compare the length of survival between these 2 groups of subjects. Other purposes of the study are to learn about the safety of DN24-02, to learn if it delays the time until urothelial cancer recurs, and to learn if the immune system responds to treatment with DN24-02. All subjects will be followed for this study for the remainder of their lives. |
Link: |
A Randomized, Phase 2, Open-Label Study Evaluating DN24-02 as Adjuvant Therapy |
Site: |
Johns Hopkins Hospital |
Principal Investigator: |
Dr. Jenny Kim, MD |